TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

By F. Demichelis, K. Fall, S. Perner, O. Andrén, F. Schmidt, S. Setlur, Yujin Hoshida, J. Mosquera, Y. Pawitan, Charles Lee and 7 more. Oncogene, 2007

595 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/64fc45bb3fdeac82456532a981a499f10604f715

Citations in the corpus

• Role of the TMPRSS2-ERG gene fusion in prostate cancer. (2008, unknown): “…molecular sub-type, with multiple studies showing that approximately 50% of prostate cancers from prostate-specific antigen (PSA) screened surgical cohorts are TMPRSS2 – ERG fusion-positive, and greater than 90% of prostate cancers over-expressing ERG harbor TMPRSS2 – ERG fusions [2,4 – 18].”